Invest in the Future of Cancer Therapy

Presentations & Factsheets

• Non-Confidential Deck
• Investor fact sheet

Scientific Publications & Literature

1. Design of novel Antibody Drug Conjugates using a fully humanized monoclonal antibody targeting the human Neuronal Pentraxin Receptor (YB800-ADCs) for therapeutic intervention in Oncology. Schiemann, P., Janicot, M., Wennemuth, G., Lyndin, M. & Moyer, J. J. Natl. Compr. Canc. Netw. 23: PCO25-210 (2025).
2. Design of novel antibody drug conjugates using a fully humanized monoclonal antibody targeting the human neuronal pentraxin receptor (YB800-ADCs) for therapeutic intervention in Oncology. Janicot, M., Wennemuth, G., Lyndin, M., Moyer, J. & Schiemann, P. 2025 NCCN Annual Conference. Orlando, FL. March 28-30, 2025.
3. Design of radioimmunoconjugates based on a humanized monoclonal antibody (YB-800) targeting the human neuronal pentraxin receptor (NPTXR) for diagnostic or therapeutic intervention in cancer patients. Janicot, M., Behe, M., Wennemuth, G., Lyndin, M. & Schiemann, P. 2024 Targeted RadioPharmaceuticals Annual Summit. Amsterdam, The Netherlands. December 3-5, 2024.
4. YB-800, a monoclonal antibody targeting the human neuronal pentraxin receptor (NPTXR), as a potential candidate for the design of a first in class antibody drug conjugate (ADC) as novel therapeutic intervention in gastro-intestinal cancers. Janicot, M., Wennemuth, G., Lyndin, M., Moyer, J. & Schiemann, P. J. Clin. Oncol. 42: Number 16_suppl (2024).
5. YB-800, a monoclonal antibody targeting the human neuronal pentraxin receptor (NPTXR), as a potential candidate for the design of a first in class antibody drug conjugate (ADC) as novel therapeutic intervention in gastro-intestinal cancers. Janicot, M., Wennemuth, G., Lyndin, M., Moyer, J. & Schiemann, P. 2024 ASCO Annual Meeting. Chicago, IL. May 31 – June 4, 2024.